Navigation Links
OncoGenex to Present at Credit Suisse Healthcare Investor Conference
Date:11/5/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 5, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2013 at 8:30 a.m. MST at the Phoenician Hotel in Scottsdale, Arizona.

A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. The webcast replay will be archived for 60 days.

Highlights from the presentation can be followed on the new OncoGenex Investor Relations Twitter account at: http://twitter.com/@OncoGenex_IR.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
2. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
3. MGB Biopharma to Present at Bio-Europe 2013
4. First Annual Michael SanInocencio Lennox-Gastaut Syndrome Research Award Presented at Annual Meeting of the Child Neurology Society
5. RSC New England Clinicians to Present at RESOLVE New England’s 20th Annual Conference on November 2nd, 2013
6. MiMedx To Present At Canaccord Genuity Medical Technology And Diagnostics Forum
7. Successful Pediatric Studies: Key Study Design and Operational Considerations, a New Webinar Presented by Premier Research and Xtalks
8. ClearPath Workforce Management Expert to Present on Contractor Payroll, Engagement and Compliance as Part of Institute for Human Resources Virtual Conference
9. Z Trim to Present at the 2013 Clean Label Conference
10. Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting’s 3rd World Drug Discovery Online Conference
11. Rancho BioSciences will present the tranSMART open source platform at TM Forum’s Digital Disruption 2013, Oct 28-31, San Jose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
(Date:2/23/2017)... 23, 2017  Seattle,s upscale Capitol Hill neighborhood, with its swanky ... for a head lice treatment salon to set up shop. ... restaurant and a French bistro on E Madison Ave, and ... just any old lice clinic, we pride ourselves on being ... release some of the stigma associated with lice. Everyone can ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... (FDA) de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® ... adults at home or in healthcare facilities during periods of rest. A lightweight, ...
(Date:2/23/2017)... INDIANAPOLIS, Ind. (PRWEB) , ... February 23, 2017 ... ... Commercialization Award during the 12th annual Inventors Recognition Reception at Purdue Research ... annually to a faculty member in recognition of outstanding contributions to, and success ...
Breaking Biology Technology:
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/1/2017)... February 1, 2017 IDTechEx Research, a leading ... technology, announces the availability of a new report, Sensors for ... Continue Reading ... ... collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and ...
(Date:1/25/2017)... The Elements of Enterprise Information Security ... of a comprehensive set of business processes and ... identities and providing a secured and documented access ... number of programs opted by enterprises to maintain ... processes and changing policies. However, there are some ...
Breaking Biology News(10 mins):